Capivasertib联合恩扎卢胺治疗多西他赛后且阿比特龙治疗后的转移性去势抵抗性前列腺癌:随机II期RE-AKT试验结果
RE-AKT是一项双盲、安慰剂对照、随机II期试验,纳入100例既往阿比特龙和多西他赛后进展的转移性去势抵抗性前列腺癌患者,1:1随机接受恩扎卢胺联合capivasertib或安慰剂。复合缓解率在两组分别为19.1%和18.8%,差异无统计学意义;PTENIHC缺失亚组结果相似。联合治疗耐受性良好。
要点
- capivasertib联合恩扎卢胺的复合缓解率为19.1%,安慰剂组为18.8%,差异无统计学意义。
- PTENIHC缺失亚组中两组结果相似。
- 无论治疗分组,PTENIHC缺失者总生存显著更差(10.1个月 vs 14.8个月,p=0.02)。
核心结论
- capivasertib联合恩扎卢胺耐受性良好,但未显著改善既往阿比特龙治疗后的转移性去势抵抗性前列腺癌患者的结局。
研究设计与样本
- 双盲、安慰剂对照、随机II期试验,从15个英国中心招募≥18岁、体能状态0-2、正在进展的转移性去势抵抗性前列腺癌男性患者。
- 共100例参与者按1:1随机(50:50),其中95例可评估主要终点(47:48);中位随访43个月。
- 随机接受恩扎卢胺(160 mg口服,每日一次)联合capivasertib(400 mg)或安慰剂口服,每日两次,间歇给药方案(用药4天、停药3天)。
主要发现
- 复合缓解率在恩扎卢胺/capivasertib组为9/47(19.1%),在恩扎卢胺/安慰剂组为9/48(18.8%),绝对差异0.4%(90%CI -12.8至13.6,p=0.58)。
- PTENIHC缺失亚组中两组结果相似。
- 无论治疗分组,PTENIHC缺失者的总生存显著更差:10.1个月(95%CI 4.6-13.9)vs 14.8个月(95%CI 10.8-18),p=0.02。
- 联合治疗最常见的≥3级治疗中出现的不良事件为腹泻(13% vs 2%)和疲乏(10% vs 6%)。
关键数值与推荐
- 主要终点为复合缓解率,包括RECIST 1.1客观缓解、PSA较基线下降≥50%、或循环肿瘤细胞计数转化(从基线≥5个至<5个/7.5 mL)。
- 按PTENIHC状态的亚组分析为预先计划。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PTEN loss and aberrations in PI3K/AKT signaling kinases associate with poorer response to abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). In this study, we assessed antitumor activity of the AKT inhibitor capivasertib combined with enzalutamide in mCRPC with prior progression on AA and docetaxel. METHODS: This double-blind, placebo-controlled, randomized phase 2 trial, recruited men ≥ 18 years with progressing mCRPC and performance status 0-2 from 15 UK centers. Randomized participants (1:1) received enzalutamide (160 mg orally, once daily) with capivasertib (400 mg)/ placebo orally, twice daily on an intermittent (4 days on, 3 days off) schedule. Primary endpoint was composite response rate (RR): RECIST 1.1 objective response, ≥ 50 % PSA decrease from baseline, or circulating tumor cell count conversion (from ≥ 5 at baseline to < 5 cells/7.5 mL). Subgroup analyses by PTENIHC status were pre-planned. RESULTS: Overall, 100 participants were randomized (50:50); 95 were evaluable for primary endpoint (47:48); median follow-up was 43 months. RR were 9/47 (19.1 %) enzalutamide/capivasertib and 9/48 (18.8 %) enzalutamide/placebo (absolute difference 0.4 % 90 %CI -12.8 to 13.6, p = 0.58), with similar results in the PTENIHC loss subgroup. Irrespective of treatment, OS was significantly worse for PTENIHC loss (10.1 months [95 %CI: 4.6-13.9] vs 14.8 months [95 %CI: 10.8-18]; p = 0.02). Most common treatment-emergent grade ≥ 3 adverse events for the combination were diarrhea (13 % vs 2 %) and fatigue (10 % vs 6 %). CONCLUSIONS: Combined capivasertib/enzalutamide was well tolerated but didn't significantly improve outcomes from abiraterone pre-treated mCRPC.
引用
- Rescigno P, Porta N, Finneran L, et al. Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. Eur J Cancer. 2024. PMID: 38729054. doi:10.1016/j.ejca.2024.114103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。